Traders should monitor for IDE submission confirmation and FDA feedback in Q2 2026, which could serve as a near-term catalyst. Positive engagement may support valuation despite lack of current revenue, given the large CGM market opportunity.
Price Chart
Executive Summary
Glucotrack, Inc. announced progress toward submitting an Investigational Device Exemption (IDE) application to the FDA for its fully implantable continuous blood glucose monitoring (CBGM) system, with a target filing in Q2 2026. The company highlighted completion of a first-in-human study in Brazil showing strong accuracy (MARD 7.7%) and safety, initiation of a follow-up trial in Australia, recent patent grants, and readiness for a U.S. clinical trial pending FDA feedback.
Key Facts
- Completed first-in-human trial in Brazil with 10 diabetic patients; met all primary and secondary endpoints.
- Reported MARD of 7.7%, 99% data capture rate, and no serious adverse events in the Brazil trial.
- Initiated feasibility trial in Australia in July 2025, yielding product and protocol improvements.
- Awarded three key U.S. patents (US 12,453,494, US 12,458,257, US 12,458,258) covering sensor chemistry, lead design, and electronics.
- Prepared for U.S. clinical trial with site secured, CRO engaged, and product enhancements completed; IDE submission targeted for Q2 2026.
- No revenue or financial results disclosed; company remains in development stage.
Financial Impact
No immediate financial impact; potential long-term value if FDA trials succeed and product reaches market.
Risk Factors
- FDA may not approve IDE submission or may require additional preclinical data, delaying trials.
- Company has no commercial products or revenue and remains dependent on future financing to fund operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263732 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.4032 | awaiting T+60 | — | $1.61 (−299.31%) |
Oct 19, 2026 7d ago | 8-K | $0.6511 | awaiting T+60 | — | $1.61 (+147.27%) |
Oct 13, 2026 13d ago | S-1/A | $0.8873 | awaiting T+60 | — | $1.61 (−81.45%) |
Oct 13, 2026 13d ago | 425 | $0.8873 | awaiting T+60 | — | $1.61 (+81.45%) |
Sep 28, 2026 28d ago | 8-K | $1.74 | awaiting T+60 | — | $1.61 (−7.47%) |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | $1.61 (+11.54%) |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | $1.61 (+11.54%) |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | $1.61 (−20.69%) |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | $1.61 (−20.69%) |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | $1.61 (−30.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers